Morphological alterations in the brains of schizophrenia patients suggest that neurodevelopmental dysfunction is involved in the etiology of the disease.
Cell adhesion molecules (CAMs) play important roles in specifying cell-cell interactions during development, regeneration, and modification of synaptic activity. In humans, mutations in the L1 cell adhesion molecule (L1CAM) are associated with a neurological syndrome termed CRASH, which includes corpus callosum agenesis, mental retardation, adducted thumbs, spasticity, hydrocephalus, and a wide spectrum of other clinical features. A mouse model with null mutation in the L1CAM gene suggests roles for L1CAM in the mechanism of cortical dendrite differentiation as well as in guidance of callosal axons and regulation of hippocampal development. 2 An abnormality in expression of one of the CAMs could result in the histologic abnormalities observed in the brains of individuals with schizophrenia. 3 Increased neural CAM (NCAM) and decreased L1CAM immunoreactivities have been observed in the cerebrospinal fluid (CSF) of schizophrenic patients in comparison to immunoreactivities in normal control subjects. 4, 5 A selective increase in levels of 105-to 115-kDa NCAM in the hippocampi and prefrontal cortices of patients with schizophrenia was found, though levels of other NCAMs and L1CAM were not altered. 6, 7 Since NCAMs function can be impaired by viral neuroaminidase associated with maternal influenza infection during embryonic development, 8 and since increased CSF NCAM and decreased CSF L1CAM levels were found in affected but not non-affected twins in a study of monozygotic discordant twins, the changes in NCAMs observed in schizophrenia may not contribute to the genetic predisposition to schizophrenia. 4 However, schizophrenia is known to have a genetic component, and a cohort study suggested an interaction between genetic risk for schizophrenia and obstetric complications. 9, 10 It is possible that mutations in the genes encoding CAMs are part of the genetic background that is influenced by environmental factors and lead to the abnormal neural development observed in schizophrenia. Genetic studies have not provided evidence for involvement of NCAM1 gene mutations in the development of schizophrenia, 11 but a possible association between an intronic polymorphism of the L1CAM gene on Xq28 and schizophrenia in male subjects has been reported. 12 The L1 family of neural recognition molecules is part of the Ig superfamily. 13 Members of the L1 family are characterized by six Ig-like domains at the N-terminus of the protein and at least four fibronectin type III (FN) homologous repeats.
14 Members of this family are either homophilic or heterophilic. A recently identified close homologue of L1 (CHL1, also called CALL (cell adhesion L1-like)) is a member of this family and is a powerful promoter of neurite outgrowth. 14, 15 CHL1 is expressed during brain development at times of neurite outgrowth. Expression of CHL1 and L1CAM show overlapping but distinct patterns in neurons and glia, suggesting differential effects of L1-like molecules on neurite outgrowth. 15 The continued expression of CHL1 throughout adulthood suggests that CHL1 protein functions in the adult nervous system.
We consider CHL1 to be a candidate gene for schizophrenia on the basis of the link between abnormal neurodevelopment and schizophrenia. The CHL1 gene is composed of 26 exons distributed over a total length of approximately 90 kb on human chromosome 3p26 (GenBank Accession Number AC011609). Although significant linkage of chromosome 3p26 to schizophrenia has not been found in genome-wide linkage studies, [16] [17] [18] [19] it is possible that the CHL1 gene has minor or modest association with the development of schizophrenia.
We screened for mutations in the CHL1 gene by sequencing all exons and exon-intron junctions in 24 randomly selected schizophrenia patients. The total length of the genomic region we examined was more than 11 kb per individual. Four variants, a C to T transition in exon 1 (320C→T, Leu17Phe), a T to A transversion 3 bp upstream of exon 2 (IVS1-3T→A), a G to A transition 41 bp upstream of exon 8 (IVS7-41G→A), and an A to G transition 6 bp downstream of exon 9 (IVS9+6A→G), were identified ( Figure 1 ). The frequency of each variant was 0.36, 0.01, 0.48, and 0.03, respectively, in 48 randomly selected control subjects ( Figure 1 ). We examined associations of the Leu17Phe and IVS7-41G/A polymorphisms with schizophrenia by determining the genotype of these polymorphisms in 282 unrelated Japanese patients with schizophrenia and 229 unrelated Japanese control subjects. Genotypic distributions of these two polymorphisms did not deviate significantly from Hardy-Weinberg equilibrium.
The frequency of the Leu17 allele was significantly higher in the schizophrenic group (0.71) than in the control group (0.63) (P = 0.006, Table 1 ). The estimated odds ratio for schizophrenia was 1.45 for the Leu17 The data of schizophrenic patients were compared with those of control subjects by using the 2 test (df = 2) for genotype distributions and by Fisher's exact test (two-sided) for allele distributions.
Molecular Psychiatry allele compared with the Phe17 allele (95% CI, 1.15-1.89). This association was due to the higher frequency of homozygosity for the Leu17 allele in the schizophrenia group than in the control group. The estimated odds ratio for schizophrenia was 1.83 (95% CI, 1.28-2.26) for the Leu/Leu genotype in comparison to the other genotypes. There was no significant association between the polymorphism and age at onset of schizophrenia, subtypes of schizophrenia, or the presence or absence of a family history of schizophrenia. The Leu1-7Phe genotypes were not significantly associated with onset age (P = 0.19) or subtypes (P = 0.12) in the schizophrenic patients.
The frequency of the G allele of the IVS7-41G/A polymorphism was higher in the schizophrenic group (0.60) than in the control group (0.54), though the difference was not significant (P = 0.056). The Leu17Phe and IVS7-41G/A polymorphisms were in modest linkage disequilibrium in the schizophrenic (D = 0.06 and DЈ = 0.35) and control (D = 0.07 and DЈ = 0.35) groups. Therefore, the relatively high frequency of the G allele of the IVS7-41G/A polymorphism in the schizophrenic group is likely to be due to an association between the Leu17Phe polymorphism and schizophrenia in the population.
The leucine at amino acid 17 is contained within the signal peptide (most likely cleavage site is between residues 24 and 25) and is conserved in the mouse Chl1 protein. Signal peptides play a critical role in the tar-geting of proteins to the endoplasmic reticulum and translocation of proteins across the membrane. They typically have three distinct domains: a positively charged amino-terminal region, a central hydrophobic core region, and a more polar carboxyl-terminal domain. 20 Leu17 is in the hydrophobic core region. Some mutations in the hydrophobic regions of signal sequences have been reported to have a direct correlation with defective protein synthesis and pathological status: a Trp9Ser mutation in L1CAM was found in a patient with X-linked hydrocephalus, 21 a Leu9Pro mutation in cathepsin K in a patient with pycnodysostosis, 22 a Cys18Arg mutation in preproparathyroid hormone has been identified in familial isolated hypoparathyroidism, 23 a Leu15Arg mutation in bilirubin UDP-glucuronosyltransferase was found in patients with Crigler-Najjar (CN) disease, 24 and a Pro5Arg mutation in ␣-L-fucosidase was reported in a patient with fucosidosis. 25 These mutations may disrupt the hydrophobic core of signal sequences by substituting either charged or helix-breaking residues. Although the Leu to Phe substitution at amino acid 17 of the CHL1 protein is not predicted to significantly disrupt the hydrophobic core, the substitution may cause a somewhat kinetic change in translocation.
The association between the Leu17Phe gene polymorphism and schizophrenia observed in this study suggests that the CHL1 protein is involved in the etiology of schizophrenia. However, caution is required because there is no evidence that the CHL1 protein is altered in the brain of schizophrenic patients and because case-control studies are susceptible to positive and negative artifacts from unknown population stratifications. Because the control group in the present study was recruited from among hospital staff members who were determined to be psychosis free and other staff members who were apparently healthy but had not been evaluated for psychiatric disorders, it is possible that the significant difference in genotype distributions comes from population stratification. It is also possible that the Leu17Phe polymorphism is in linkage disequilibrium with an unidentified polymorphism that influences expression or primary structure of the CHL1 protein. Future studies, particularly familybased association studies, are needed to confirm the association. Data from the present study provide a basis for future studies of the role of the CHL1 gene in schizophrenia.
Materials and methods

Subjects
The schizophrenia subjects included in this study were 282 unrelated Japanese patients with schizophrenia (152 men and 130 women, age (mean ± SD) 45.9 ± 11.4 years). They were recruited from among patients being treated at one of six hospitals near Tokyo in Japan. All patients satisfied the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Third Edition Revised (DSM-III-R), for schizophrenia. Patients were further classified by clinical subtypes (134 paranoid, 76 disorganized, 12 catatonic, 37 residual, and 23 undifferentiated). Control subjects comprised 229 anonymous, unrelated Japanese individuals (135 men and 94 women, 47.3 ± 11.5 years of age). One hundred and thirty-five were hospital staff members who were psychosis-free; the remaining 94 were recruited from apparently healthy staff employees who were not evaluated for psychiatric disorders. This study was approved by the Ethics Committees of Tsukuba University and Tokyo Medical and Dental University. All subjects gave written informed consent.
DNA analysis
Genomic DNA was extracted from peripheral blood leukocytes collected from subjects by a standard phenol extraction procedure. DNA fragments including all exons, were amplified by polymerase chain reaction (PCR) with primers listed on our web site (http://www.md.tsukuba.ac.jp/public/basic-med/ m-genetics/CHL1Primers.htm). The genomic structure of the CHL1 gene and primer pairs were determined from GenBank Accession No. AC011609. To screen for nucleotide variants, direct sequencing of amplified PCR products was carried out in 24 randomly selected schizophrenia patients.
PCR amplification was done in a final volume of 15 l consisting of 2 ng genomic DNA, 2.5 pM deoxyribonucleotides, 3.1 pM of each primer, 10 mM Tris HCl (pH 9.0), 50 mM KCl, 2 mM MgCl 2 , 10% dimethylsulfoxide, and 0.25 U AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA, USA). Reactions were incubated for 5 min at 94°C, followed by 30 cycles of denaturation at 95°C for 30 s, annealing at 48-65°C for 30 s, and extension at 72°C for 45 s, each amplification was finished with a final cycle of 72°C for 3 min. The specific annealing temperatures for primers are also shown on our web site. Direct sequencing was carried out with the Big Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems) on an ABI 3100 autosequencer (Applied Biosystems). The genotype for Leu17Phe polymorphism was determined by restriction fragment length polymorphism (RFLP) analysis with Mnl I after PCR amplification with primers 5Ј-GGTATTTAATTTGTTCTGTTG and 5Ј-TAGAAAAGTCACATCCTCAATCC. The annealing temperature for the PCR was 50.0°C. The 350-bp PCR product with the Leu17 allele was cleaved by Mnl I to generate 104-, 103-, 75-, 43-, and 25-bp fragments, whereas that containing the Phe17 allele yielded 147-, 103-, 75-, and 25-bp fragments. The fragments were separated on 3% agarose and 1.5% Nu-Sieve gels, and the bands were visualized by ethidium bromide staining and ultraviolet transillumination. The genotype of the IVS7-41G/A polymorphism was determined by RFLP analysis with AciI after PCR amplification with primers 5Ј-GCACCCTGATAAAGGATGTG and 5Ј-GGGCGTAAATGACAAACCTG. The annealing temperature for PCR was 52.0°C. The 452-bp PCR product containing the IVS7-41G allele was cleaved by AciI to generate 351-, 52-, and 49-bp fragments, whereas that containing the IVS-41A allele yielded 403-and 49-bp fragments. Non-digestion or partial digestion of the PCR products was monitored by comparison to undigested PCR fragment bands. All genotypes were recorded independently by the first and second authors of this paper without knowledge of diagnostic status and the genotypes scored by the two recorders were identical.
Statistical analysis
Case-control comparisons were made by 2 test and Fisher's exact test. Linkage disequilibrium statistics (D), standardized disequilibrium statistics (DЈ = D/Dmax), and significance of linkage disequilibrium were computed from estimated haplotype frequencies with Arlequin 2.0 (http://anthropologie.unige.ch/ arlequin). A P value of 0.05 was considered significant in tests for Hardy-Weinberg equilibrium. When allelic and genotypic distributions of each polymorphism were compared between the patient and control groups, correction of four for multiple testing was made (P Ͻ 0.0125) because we tested allelic and genotypic distributions of two polymorphisms. Associations between the Leu17Phe genotypes and onset age or clinical subtypes for the schizophrenic cases were assessed by ANOVA or 2 test.
